Cargando…

Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome

Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Ashraf F, Abraham, Bishoy, Hanna, Andrew, Smith, Adam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571854/
https://www.ncbi.nlm.nih.gov/pubmed/28860873
http://dx.doi.org/10.2147/IMCRJ.S137975
_version_ 1783259420201844736
author Hanna, Ashraf F
Abraham, Bishoy
Hanna, Andrew
Smith, Adam J
author_facet Hanna, Ashraf F
Abraham, Bishoy
Hanna, Andrew
Smith, Adam J
author_sort Hanna, Ashraf F
collection PubMed
description Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics, and other pharmacotherapies. The patient commenced an experimental intravenous ketamine infusion therapy at the Florida Spine Institute (Clearwater, FL, USA) and achieved relief from her chronic pain, an improved quality of life, reduced depression and suicidal ideation, and reduced opioid consumption.
format Online
Article
Text
id pubmed-5571854
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55718542017-08-31 Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome Hanna, Ashraf F Abraham, Bishoy Hanna, Andrew Smith, Adam J Int Med Case Rep J Case Report Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics, and other pharmacotherapies. The patient commenced an experimental intravenous ketamine infusion therapy at the Florida Spine Institute (Clearwater, FL, USA) and achieved relief from her chronic pain, an improved quality of life, reduced depression and suicidal ideation, and reduced opioid consumption. Dove Medical Press 2017-08-18 /pmc/articles/PMC5571854/ /pubmed/28860873 http://dx.doi.org/10.2147/IMCRJ.S137975 Text en © 2017 Hanna et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Hanna, Ashraf F
Abraham, Bishoy
Hanna, Andrew
Smith, Adam J
Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
title Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
title_full Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
title_fullStr Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
title_full_unstemmed Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
title_short Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome
title_sort effects of intravenous ketamine in a patient with post-treatment lyme disease syndrome
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571854/
https://www.ncbi.nlm.nih.gov/pubmed/28860873
http://dx.doi.org/10.2147/IMCRJ.S137975
work_keys_str_mv AT hannaashraff effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome
AT abrahambishoy effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome
AT hannaandrew effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome
AT smithadamj effectsofintravenousketamineinapatientwithposttreatmentlymediseasesyndrome